Author

CK Anders

Observed name: C Anders

Institutions: University of North Carolina at Chapel Hill, Duke University Hospital, Duke Cancer Institute

Observed institutions: University of North Carolina at Chapel Hill, Eli Lilly (United States), University of California, San Francisco, Living Beyond Breast Cancer, Triple Negative Breast Cancer Foundation, Dana-Farber Cancer Institute, Duke University Hospital, Genomic Health (United States), Vall d'Hebron Institute of Oncology, Duke Cancer Institute, UNC Lineberger Comprehensive Cancer Center, Medical University of Vienna, University of Pennsylvania

OpenAlex ID: A5000235117

Abstract P6-11-06: Efficacy of carboplatin alone or with ABT888 in an intracranial murine model of BRCA-mutated, basal-like, triple negative breast cancer (TNBC)

2013 · O Karginova, B Adamo, et al. · Cancer Research · 1

Abstract P1-06-04: Small-molecule screening nominates diverse combination therapies that sensitize BRCA mutant and wild-type triple negative breast cancer to PARP inhibition

2019 · S Sammons, C Yip, et al. · Cancer Research

Abstract P1-05-20: Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill

2017 · TA Jolly, JE Grilley-Olson, et al. · Cancer Research

Abstract P5-09-09: Preferences in educational topics of interest for women with breast cancer: Does age influence topic preferences?

2016 · KD Swiger, JE Guglielmino, et al. · Cancer Research

Abstract OT1-03-04: A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer

2016 · C Anders, C Zielinski, et al. · Cancer Research

P2-14-01: Race, Response to Chemotherapy, and Outcome within Clinical Breast Cancer Subtypes.

2011 · JR Tichy, AM Deal, et al. · Cancer Research

Works count: 6

Citation count: 1

H-index: 1

I10-index: